secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
CIK:        0001500198
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001213900-25-042270
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroOne Q2 net loss narrows to $2.3M; gross margin up to 55.6%
---------------------------------------------------------------

- Q2 product revenue $1.4M flat YoY; H1 product revenue up 98% to $4.7M.
- Q2 product gross margin 55.6% vs 28.3% YoY; FY25 guidance reaffirmed ($8-10M revenue).
- Filed 510(k) for OneRF Trigeminal Nerve Ablation System for facial pain ahead of schedule; potential revenue in late CY2025.
- Raised $8.2M net in oversubscribed institutional offering in April; cash $9.4M post-raise; debt-free.
- Hired Dr. Parag Patil as Chief Medical Advisor and Emily Johns as General Counsel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1500198/000121390025042270/0001213900-25-042270-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1500198/000121390025042270/ea0241742-8k_neuroone.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-042270

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer